Achieve Life Sciences
ACHV
66 hedge funds and large institutions have $59.4M invested in Achieve Life Sciences in 2025 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 14 reducing their positions, and 26 closing their positions.
411% more call options, than puts
Call options by funds: $480K | Put options by funds: $94K
327% more capital inflows, than outflows
Capital inflows: $44.3M | Capital outflows: $10.4M
64% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 14
34.2% more ownership
Funds ownership: 41.54% → 75.73% (+34%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 73 → 66 (-7)
27% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Propel Bio Management
Los Angeles,
California
|
+$10.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$8.78M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$5.7M |
| 4 |
Clearline Capital
New York
|
+$3.78M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$3.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.95M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$1.16M |
| 3 |
State Street
Boston,
Massachusetts
|
-$842K |
| 4 |
J. Goldman & Co
New York
|
-$785K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$536K |
ACHV Hedge Fund Activity: Q2 2025 in Review
66 of the 7,627 institutional investors tracked by Wall St. Rank reported a position in Achieve Life Sciences (ACHV) for Q2 2025, worth a combined $59.4M — up 54% from $38.5M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of ACHV and 19 opened new positions — a net loss of 7 holders — while 14 trimmed existing stakes and 23 added.
The largest buyer was Propel Bio Management, adding an estimated $10.5M. The largest seller was BlackRock, cutting an estimated $4.95M.
- 66 institutional investors held Achieve Life Sciences (ACHV) as of Q2 2025, down from 73 in Q1 2025.
- Funds reported $59.4M of Achieve Life Sciences stock for Q2 2025, up 54% quarter-over-quarter.
- 19 funds opened new Achieve Life Sciences positions in Q2 2025 and 26 closed out, a net change of -7 holders.
- The largest Achieve Life Sciences buyer in Q2 2025 was Propel Bio Management, an estimated $10.5M added.
- The largest Achieve Life Sciences seller in Q2 2025 was BlackRock, an estimated $4.95M sold.
Based on aggregated 13F filings for Q2 2025.